BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 29793403)

  • 1. Active surveillance of men with low risk prostate cancer: evidence from the Prostate Cancer Outcomes Registry-Victoria.
    Evans MA; Millar JL; Earnest A; Frydenberg M; Davis ID; Murphy DG; Kearns PA; Evans SM
    Med J Aust; 2018 Jun; 208(10):439-443. PubMed ID: 29793403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011.
    Evans SM; Millar JL; Davis ID; Murphy DG; Bolton DM; Giles GG; Frydenberg M; Andrianopoulos N; Wood JM; Frauman AG; Costello AJ; McNeil JJ
    Med J Aust; 2013 Jun; 198(10):540-5. PubMed ID: 23725268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The current use of active surveillance in an Australian cohort of men: a pattern of care analysis from the Victorian Prostate Cancer Registry.
    Weerakoon M; Papa N; Lawrentschuk N; Evans S; Millar J; Frydenberg M; Bolton D; Murphy DG
    BJU Int; 2015 Apr; 115 Suppl 5():50-6. PubMed ID: 25601201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Follow-up in Active Surveillance for Prostate Cancer: Strict Protocol Adherence Remains Important for PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2019 Sep; 2(5):483-489. PubMed ID: 31411970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.
    Sathianathen NJ; Konety BR; Alarid-Escudero F; Lawrentschuk N; Bolton DM; Kuntz KM
    Eur Urol; 2019 Jun; 75(6):910-917. PubMed ID: 30425010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in treatment choices for localised prostate cancer diagnosed in private and public health services.
    Te Marvelde L; Milne RL; Hornby CJ; Chapman AB; Giles GG; Haines IE
    Med J Aust; 2020 Nov; 213(9):411-417. PubMed ID: 32996611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time Trends and Variation in the Use of Active Surveillance for Management of Low-risk Prostate Cancer in the US.
    Cooperberg MR; Meeks W; Fang R; Gaylis FD; Catalona WJ; Makarov DV
    JAMA Netw Open; 2023 Mar; 6(3):e231439. PubMed ID: 36862409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression.
    Wong LM; Alibhai SM; Trottier G; Timilshina N; Van der Kwast T; Zlotta A; Lawrentschuk N; Kulkarni G; Hamilton R; Ferrara S; Margel D; Trachtenberg J; Jewett MA; Toi A; Evans A; Fleshner NE; Finelli A
    Eur Urol; 2014 Sep; 66(3):406-13. PubMed ID: 23664820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of early transperineal template-guided prostate biopsy for risk stratification in men undergoing active surveillance for prostate cancer.
    Voss J; Pal R; Ahmed S; Hannah M; Jaulim A; Walton T
    BJU Int; 2018 Jun; 121(6):863-870. PubMed ID: 29239082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRI-Based Prostate-Specific Antigen Density Predicts Gleason Score Upgrade in an Active Surveillance Cohort.
    Washington SL; Baskin AS; Ameli N; Nguyen HG; Westphalen AC; Shinohara K; Carroll PR
    AJR Am J Roentgenol; 2020 Mar; 214(3):574-578. PubMed ID: 31913068
    [No Abstract]   [Full Text] [Related]  

  • 13. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
    Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer Location in Upgrading and Detection after Transperineal Template-Guided Mapping Biopsy for Patients in Active Surveillance and Negative Transrectal Ultrasonography-Guided Prostate Biopsy.
    Lee CU; Sung SH; Jang CT; Kang M; Sung HH; Jeong BC; Seo SI; Jeon SS; Lee HM; Jeon HG
    Urol Int; 2019; 103(3):262-269. PubMed ID: 31269509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies.
    Cary KC; Cowan JE; Sanford M; Shinohara K; Perez N; Chan JM; Meng MV; Carroll PR
    Eur Urol; 2014 Aug; 66(2):337-42. PubMed ID: 24035632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance.
    Radtke JP; Kuru TH; Bonekamp D; Freitag MT; Wolf MB; Alt CD; Hatiboglu G; Boxler S; Pahernik S; Roth W; Roethke MC; Schlemmer HP; Hohenfellner M; Hadaschik BA
    Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):283-91. PubMed ID: 27184812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Fenton JJ; Weyrich MS; Durbin S; Liu Y; Bang H; Melnikow J
    JAMA; 2018 May; 319(18):1914-1931. PubMed ID: 29801018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
    van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
    BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
    Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
    JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Confirmatory biopsy of men under active surveillance: extended versus saturation versus multiparametric magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy.
    Pepe P; Cimino S; Garufi A; Priolo G; Russo GI; Giardina R; Reale G; Pennisi M; Morgia G
    Scand J Urol; 2017 Aug; 51(4):260-263. PubMed ID: 28513296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.